title: Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Phillips
authors.forename: Anna
authors.initials: A
authors.lastname: Hayden
authors.forename: Sonia
authors.initials: S
authors.lastname: Gutiérrez
authors.forename: Natalie
authors.initials: N
authors.lastname: Jahnke
authors.forename: Benita
authors.initials: B
authors.lastname: Yip
authors.forename: Viviane D
authors.initials: VD
authors.lastname: Lima
authors.forename: Robert S
authors.initials: RS
authors.lastname: Hogg
authors.forename: P Richard
authors.initials: PR
authors.lastname: Harrigan
authors.forename: Julio S G
authors.initials: JS
authors.lastname: Montaner
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D015658:HIV Infections / Q000401:mortality; D019698:Hepatitis C, Chronic / Q000401:mortality; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine